From WikiMD Wellnesspedia & World Directory
What is Wegovy?
WEGOVY(Semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients who are obese.
What are the uses of this medicine?
Wegovy is approved for chronic weight management in adult patients(in addition to diet and exercise) with an initial body mass index (BMI) of
- 30 kg/m2 or greater (obesity) or
- 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).
How does this medicine work?
- Semaglutide, the active ingredient in Wegovy, is a human GLP-1 receptor agonist (or GLP-1 analog).
- Wegovy works by mimicking a hormone called glucagon-like peptide-1 (GLP-1) that targets areas of the brain that regulate appetite and food intake.
What are the dosage forms and brand names of this medicine?
Injection: pre-filled, single-dose pen that delivers doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg or 2.4 mg
How should this medicine be used?
- Administer WEGOVY once weekly, on the same day each week, at any time of day, with or without meals.
- Inject subcutaneously in the abdomen, thigh or upper arm
- Initiate at 0.25 mg once weekly for 4 weeks. In 4 week intervals, increase the dose until a dose of 2.4 mg is reached.
- The maintenance dose of WEGOVY is 2.4 mg once weekly.
- In patients with type 2 diabetes, monitor blood glucose prior to starting and during WEGOVY treatment.
Is this medicine FDA approved?
Yes, on June 4th, 2021.
Who Should Not Use this medicine ?
- Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2.
- Known hypersensitivity to semaglutide or any of the excipients in WEGOVY.
- WEGOVY should not be used in combination with other semaglutide-containing products or any other GLP-1 receptor agonist.
- The safety and efficacy of coadministration with other products for weight loss have not been established
- WEGOVY has not been studied in patients with a history of pancreatitis.
What special precautions should I follow?
Thyroid C-cell Tumors: Boxed Warning:
- In rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures.
- It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
- WEGOVY is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors
Other warnings and precuations:
- Acute pancreatitis: Has occurred in clinical trials. Discontinue promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed.
- Acute gallbladder disease: Has occurred in clinical trials. If cholelithiasis is suspected, gallbladder studies and clinical follow-up are indicated.
- Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing the dose of insulin secretagogue or insulin may be necessary. Inform all patients of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.
- Acute kidney injury: Has occurred. Monitor renal function when initiating or escalating doses of WEGOVY in patients reporting severe adverse gastrointestinal reactions or in those with renal impairment reporting severe adverse gastrointestinal reactions.
- Hypersensitivity: Anaphylactic reactions and angioedema have been reported postmarketing. Discontinue WEGOVY if suspected and promptly seek medical advice.
- Diabetic retinopathy Complications in Patients with Type 2 Diabetes: Has been reported in trials with semaglutide. Patients with a history of diabetic retinopathy should be monitored.
- Heart rate increase: Monitor heart rate at regular intervals.
- Suicidal behavior and Ideation: Monitor for depression or suicidal thoughts. Discontinue WEGOVY if symptoms develop.
Can this medicine be used in children?
It is not studied in children
What side effects can this medication cause?
The most common adverse reactions, reported in greater than or equal to 5% of patients treated with WEGOVY are:
- abdominal pain
- abdominal distension
- hypoglycemia in patients with type 2 diabetes
- gastroenteritis, and
- gastroesophageal reflux disease.
What drug interactions can this medicine cause?
- WEGOVY delays gastric emptying.
- May impact absorption of concomitantly administered oral medications.
- Use with caution.
What to do in case of emergency/overdose?
- Overdoses have been reported with other GLP-1 receptor agonists.
- Effects have included severe nausea, severe vomiting, and severe hypoglycemia.
- In the event of overdose, appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms.
- A prolonged period of observation and treatment for these symptoms may be necessary, taking into account the long half-life of WEGOVY of approximately 1 week.
Can this medicine be used in pregnancy?
- It may cause fetal harm.
- When pregnancy is recognized, discontinue WEGOVY
What are the active and inactive ingredients in this medicine?
Who manufactures and distributes this medicine?
What should I know about storage and disposal of this medication?
- Store the WEGOVY single-dose pen in the refrigerator from 2°C to 8°C (36°F to 46°F).
- If needed, prior to cap removal, the pen can be kept from 8°C to 30°C (46°F to 86°F) up to 28 days.
- Do not freeze.
- Protect WEGOVY from light.
- WEGOVY must be kept in the original carton until time of administration.
- Discard the WEGOVY pen after use.
- Get savings cards for Wegovy (for providers - If you are a provider looking for a savings card on Wegovy, all you have to do is click on the link and select a box that says the patient has commercial insurance, then you can click on get savings card, when you can print or email a savings card.
- Register and save on wegovy (for patients once they have a savings card)
- Novo Medlink is a website by the manufacturer to get additional information by medical professionals.
Can you help answer any of these frequently asked questions on Wegovy?
- Does Wegovy burn fat?
- Can Wegovy make you tired?
- Who should not take Wegovy?
- How long can you take Wegovy?
- Can you drink wine on Wegovy?
- How does Wegovy make you feel?
- Are Wegovy and Ozempic the same?
- Do you keep Wegovy in the fridge?
- What happens when you stop Wegovy?
- What time of day should I take Wegovy?
- Do you gain weight back after Ozempic?
- Does it matter where you inject Wegovy?
- How quickly do you lose weight on Wegovy?
- Can Wegovy be stored at room temperature?
- Can you take Wegovy and metformin together?
- How much weight can you lose in a week on Wegovy?
- What is the difference between Wegovy and Saxenda?
Tired of being overweight?
W8MD's Medical Weight Loss, Sleep & Medspa
Pennsylvania weight loss
1718 Welsh Road, 2nd Floor, Ste C Philadelphia PA, 19115
175 Strafford Ave, Ste 1, Wayne PA 19087
New York weight loss
2632 E 21st Street Ste L2 Brooklyn New York 11235.
New Jersey weight loss
140 E. Evesham Road, Cherry Hill, NJ 08003.
W8MD can help?
Get rid of the pandemic weight
Think W8MD for weight loss.